Panel OIDIP is designed to be flexible, its composition can be changed over time to reflect actual needs of the clinicians.

On this actual site, you will have option to find different versions of the OIDIP panel throughout the time.

Additional analysis:

A) Certain polymorphism: patients can profit from being aware of the presence of certain aleles associated with Lactose or Glutan Intolerance, Crohn disease or susceptibility to thrombosis. At the same time, some pharmacologicaly important genetic variants may interfere with treatment and thus its awareness may prevent complications.

Based on the nature and importance of these variants, their presence in patients DNA will always be reported, unless the patient decides not to.


B) CFTR and PAH genes: Mutations in these two genes lead to two major autosomal recessive (AR) diseases with a relatively high incidence in the Czech population. By informing a proband about the fact, that he or she is a carrier (his/her DNA carries one mutated allele) of any of those two genes may lead to preventive measures. If a partner of a proband is also a carrier of a mutation in CFTR or PAH genes, then there is a 25% risk of developing a severe health problems. This analytical approach should thus lead to decrease of pathologies associated with two-allelic losses in genes CFTR or PAH in the Czech population.